European Heart Journal最新文献_第2页

Artificial intelligence in cardiac imaging: the future is now. 心脏成像中的人工智能：未来就是现在。

IF 39.3 1区医学

European Heart Journal Pub Date : 2025-10-03 DOI: 10.1093/eurheartj/ehaf621

Judith Ozkan

引用次数: 0

Traumatic interventricular septal dissection in a bicuspid aortic valve patient: a rare extension into the left ventricle. 创伤性室间隔夹层在二尖瓣主动脉瓣患者：一个罕见的延伸到左心室。

IF 35.6 1区医学

European Heart Journal Pub Date : 2025-10-01 DOI: 10.1093/eurheartj/ehaf499

Hongduan Liu, Yibing Fang, Wei Cheng

引用次数: 0

European Society of Cardiology clinical consensus statement on obesity and cardiovascular disease: 10 key points. 欧洲心脏病学会关于肥胖和心血管疾病的临床共识声明：10个关键点。

IF 35.6 1区医学

European Heart Journal Pub Date : 2025-10-01 DOI: 10.1093/eurheartj/ehaf177

Konstantinos C Koskinas, Emeline M Van Craenenbroeck, Eva B Prescott

引用次数: 0

Transthyretin amyloid cardiomyopathy: from cause to novel treatments. 转甲状腺素淀粉样心肌病：从病因到新疗法。

IF 39.3 1区医学

European Heart Journal Pub Date : 2025-10-01 DOI: 10.1093/eurheartj/ehaf667

Marianna Fontana,Alberto Aimo,Michele Emdin,Aldostefano Porcari,Scott D Solomon,Philip N Hawkins,Julian D Gillmore

{"title":"Transthyretin amyloid cardiomyopathy: from cause to novel treatments.","authors":"Marianna Fontana,Alberto Aimo,Michele Emdin,Aldostefano Porcari,Scott D Solomon,Philip N Hawkins,Julian D Gillmore","doi":"10.1093/eurheartj/ehaf667","DOIUrl":"https://doi.org/10.1093/eurheartj/ehaf667","url":null,"abstract":"Transthyretin amyloid cardiomyopathy (ATTR-CM) is a progressive disorder marked by amyloid deposition in the heart, ultimately impairing cardiac function. Recent treatment advances have paralleled an evolving understanding of ATTR-CM pathophysiology. One emerging hypothesis suggests that an imbalance between in vivo amyloid production and natural clearance may drive disease progression, a conceptual framework that still requires validation. Transthyretin (TTR) stabilizers, such as tafamidis and acoramidis, mitigate amyloid formation by promoting the native tetrameric conformation of circulating TTR, thereby slowing functional decline and prolonging survival. Similarly, TTR gene silencers inhibit hepatic TTR synthesis, and gene-editing therapy with nexiguran ziclumeran offers an additional strategy to reduce amyloid production. However, these approaches do not enhance the body's limited capacity to clear existing amyloid deposits, underscoring the need for novel agents that accelerate amyloid removal. Promisingly, monoclonal antibodies targeting TTR amyloid are under development, with early clinical trials suggesting that this passive immunotherapy may reverse disease progression and improve heart function. Ultimately, optimal management of ATTR-CM will require further elucidation of the complex interplay between amyloid formation, its structural and functional impacts, its clearance mechanisms, and the potential for myocardial reverse remodelling.","PeriodicalId":11976,"journal":{"name":"European Heart Journal","volume":"19 1","pages":""},"PeriodicalIF":39.3,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145194825","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Building trust in artificial intelligence for healthcare. 建立对医疗保健领域人工智能的信任。

IF 35.6 1区医学

European Heart Journal Pub Date : 2025-10-01 DOI: 10.1093/eurheartj/ehaf432

Judith Ozkan

引用次数: 0

Leducq-funded network: calcification-omics, molecular elucidation, and therapeutics (COMET). leducq资助的网络：钙化组学，分子阐明和治疗（COMET）。

IF 35.6 1区医学

European Heart Journal Pub Date : 2025-10-01 DOI: 10.1093/eurheartj/ehaf433

Rajeev Malhotra, Catherine M Shanahan, Clint L Miller

引用次数: 0

Artificial intelligence: challenges and opportunities. 人工智能：挑战与机遇。